Advertisement

Polycystic Kidney

You have accessRestricted Access
Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
Matteo Bargagli, Nasser A. Dhayat, Manuel Anderegg, Mariam Semmo, Uyen Huynh-Do, Bruno Vogt, Pietro Manuel Ferraro and Daniel G. Fuster

CJASN July 2020, 15 (7) 1007-1014; DOI: https://doi.org/10.2215/CJN.13861119

Add to Selected Citations
You have accessRestricted Access
ADPKD, Tolvaptan, and Nephrolithiasis Risk
Ewout J. Hoorn and Robert Zietse

CJASN July 2020, 15 (7) 923-925; DOI: https://doi.org/10.2215/CJN.07610520

Add to Selected Citations
Open Access
Burden of Proof for Tolvaptan in ADPKD
Reem A. Mustafa and Alan S.L. Yu

CJASN July 2018, 13 (7) 1107-1109; DOI: https://doi.org/10.2215/CJN.00190118

Add to Selected Citations
You have accessRestricted Access
A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease
Bharathi V. Reddy and Arlene B. Chapman

CJASN October 2017, 12 (10) 1695-1698; DOI: https://doi.org/10.2215/CJN.02830317

Add to Selected Citations